JAMA Oncology (@JAMAOnc) header
JAMA Oncology (@JAMAOnc) profile picture

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

Chicago, IL
Joined September 2014
Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)Photo by JAMA Oncology (@JAMAOnc)
Today, JAMA published Toward a Healthier Future Through Obesity Prevention and Care: The #JAMASummit Report on Obesity. 🔗 Read the full report: ja.ma/3V5L2OD #ObesityWeek #OW2026
5
1
1,056
Join JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and leading experts in #obesity research, treatment, and policy for an inside look at Toward a Healthier Future: The #JAMASummit Report on Obesity. ➡️ Register now: ja.ma/4t4day5
3
3
839
In ERBB2-positive metastatic #BreastCancer, first-line treatment is shifting beyond taxane-based induction toward newer regimens and expanded maintenance options that may change treatment sequencing and duration. ja.ma/3UHbgqv
6
40
3,557
In 2027, JAMA will convene leaders across #medicine, research, #technology, industry, and #policy to address how #AI will reshape health care and biomedical science. Learn more: ja.ma/4kAk3oA #HealthAfterAI #JAMASummit
2
6
825
📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #Cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. ja.ma/3W97574
8
13
1,811
A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? ja.ma/4B6SpW4
2
9
1,778
📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health. ➡️ Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day. 🔗 Learn more: ja.ma/48a7OYp
3
4
803
In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/4B5fVmv
5
922
Presented at #ESMO26 from @JAMA_current: In low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan showed benefit in hormone receptor–positive and hormone receptor-negative disease. ja.ma/3W0Jp4W
4
4
626
Presented at #ESMO26 from @JAMA_current: For low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan improved progression-free survival vs chemotherapy in both chemotherapy-naive patients and the overall population. ja.ma/4dRU6Nf
3
2
792
#ColorectalCancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations. ja.ma/47lx9hP
1
7
9
1,935
In #CancerCare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs. ja.ma/4zwEtTG
1
2
1
16
1,818